Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NVAX - Novavax, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.00
DETAILS
HIGH:
$25.00
LOW:
$11.00
MEDIAN:
$18.00
CONSENSUS:
$18.00
UPSIDE:
95.44%
Stock News
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb
Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
What's Going On With Novavax Stock On Friday?
Novavax Inc. (NASDAQ:NVAX) stock is trading higher on Friday in reaction to a surge in Moderna Inc. (NASDAQ:MRNA).
Novavax to Participate in BofA Securities 2026 Health Care Conference
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.
NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
Why Novavax Stock Is Trading Higher On Wednesday?
Novavax Inc. (NASDAQ:NVAX) shares are trading higher on Wednesday after the company reported better-than-expected first-quarter financial results.
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $2.93 per share a year ago.
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M ® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseases In February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology company Sanofi announced positive results from the Phase 4 COMPARE study, a head-to-head study comparing Nuvaxovid™ and Moderna's mNEXSPIKE that reinforces Nuvaxovid's well established and differentiated reactogenicity profile Novavax's C. difficile vaccine candidate prioritized with potential to enter the clinic as early as 2027 Reiterates 2026 Revenue Framework and Combined R&D and SG&A expense guidance GAITHERSBURG, Md.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Novavax (NVAX) concluded the recent trading session at $8.01, signifying a +1.01% move from its prior day's close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Outperforms Broader Market: What You Need to Know
Novavax (NVAX) concluded the recent trading session at $8.84, signifying a +2.31% move from its prior day's close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Price Targets
Novavax initiated with an Overweight at Cantor Fitzgerald
$18.00
(was $8.55)
Cantor Fitzgerald
Novavax price target raised to $11 from $10 at H.C. Wainwright
$11.00
(was $8.46)
Sean Lee
·
H.C. Wainwright
Novavax (NVAX) PT Lowered to $22 at B.Riley
$22.00
(was $7.58)
Mayank Mamtani
·
B.Riley Financial
Novavax (NVAX) PT Lowered to $25 at Jefferies
$25.00
(was $10.15)
Roger Song
·
Jefferies
Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial'
$14.00
(was $10.45)
Alec Stranahan
·
Bank of America Securities
Novavax price target lowered to $31 from $38 at Jefferies
$31.00
(was $14.36)
Roger Song
·
Jefferies
H.C. Wainwright reiterates Buy rating on Novavax after 'landmark' Sanofi deal
$19.00
(was $9.94)
Vernon Bernardino
·
H.C. Wainwright
Novavax (NVAX) Stock: $174 Price Target From Cantor Fitzgerald
$174.00
(was $80.11)
Charles Duncan
·
Cantor Fitzgerald